Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

“Forgotten Lessons” May Help Advance Colorectal Cancer Care

March 31st 2016

Alan P. Venook, MD, shares insight into the evolving treatment paradigm for colorectal cancer.

Combination Therapies Explored in Pancreatic Cancer Subgroups

March 25th 2016

To address the unmet need for better diagnostic and therapeutic modalities in pancreatic cancer, investigators at the Indiana University School of Medicine have established the Pancreatic Cancer Signature Center at the Indiana University Melvin and Bren Simon Cancer Center.

Second-Line Liposomal Irinotecan Added to NCCN Guideline for Pancreatic Cancer

March 24th 2016

The combination of liposomal irinotecan (irinotecan liposome injection; Onivyde), fluorouracil, and leucovorin has been added to the 2016 NCCN Clinical Practice Guidelines in Oncology as a second-line treatment for patients with gemcitabine-refractory metastatic pancreatic cancer.

Dr. Madoff on Selecting Patients With HCC Appropriate for Minimally Invasive Therapy

March 14th 2016

David C. Madoff, MD, professor of Radiology, vice chairman for Academic Affairs at Weill Cornell Medicine, discusses selecting patients with hepatocellular carcinoma who are candidates for minimally invasive therapy.

Pancreatic Cancer Vaccine Makes Progress in Two Late-Stage Trials

March 10th 2016

The novel therapeutic vaccine algenpantucel-L, which is genetically engineered from human cell lines, is being evaluated in two phase III trials in patients with resected pancreatic cancer (IMPRESS) and borderline resectable or locally advanced unresectable pancreatic cancer (PILLAR).

Adjuvant Care at High-Volume Centers Shows Improved Survival in Pancreatic Cancer

March 6th 2016

James L. Abbruzzese, MD, discusses the underlying disparity between high-volume centers and community medical centers affecting patients with pancreatic cancer.

Dr. Bekaii-Saab on Benefits Associated With Regorafenib for CRC

February 29th 2016

Tanios Bekaii-Saab, MD, associate professor, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, discusses the benefits patients receive with regorafenib for the treatment of colorectal cancer.

FDA Approves Everolimus for GI, Lung NETs

February 26th 2016

The FDA has approved everolimus for the treatment of adult patients with progressive, well-differentiated non-functional, locally advanced or metastatic gastrointestinal or lung neuroendocrine tumors.

Potential Biomarkers in Metastatic Colorectal Cancer

February 26th 2016

PI3K-Mutant Metastatic Colorectal Cancer

February 26th 2016

Microsatellite Instability Status in Colorectal Cancer

February 26th 2016

BRAF Testing in Colorectal Cancer

February 26th 2016

Pathways of Resistance in Metastatic Colorectal Cancer

February 26th 2016

Upfront EGFR Therapy in Metastatic Colorectal Cancer

February 26th 2016

EGFR Therapy as Upfront Colorectal Cancer Treatment

February 26th 2016

The Current Status of RAS Testing in Colorectal Cancer

February 26th 2016

Colorectal Cancer: Challenges in Next-Generation Sequencing

February 26th 2016

Practical Considerations in Molecular Testing in CRC

February 26th 2016

Prognostic and Predictive Markers in Colorectal Cancer

February 26th 2016

Salvage Therapy and Emerging Agents in Colorectal Cancer

February 25th 2016

Jennifer Wu, MD, reviews recently approved agents in refractory colorectal cancer, as well as biomarker-directed emerging therapies in the setting.